These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 2854170)
1. [Studies of vitamin K sensitivity of PIVKA-II in patients with hepatocellular carcinoma]. Furukawa M; Nakanishi T; Okuda H; Obata H Nihon Shokakibyo Gakkai Zasshi; 1988 Dec; 85(12):2583-9. PubMed ID: 2854170 [No Abstract] [Full Text] [Related]
2. Changes of plasma des-gamma-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Furukawa M; Nakanishi T; Okuda H; Ishida S; Obata H Cancer; 1992 Jan; 69(1):31-8. PubMed ID: 1309308 [TBL] [Abstract][Full Text] [Related]
3. Acarboxy prothrombin (PIVKA-II) as a marker of hepatoblastoma in infants. Motohara K; Endo F; Matsuda I; Iwamasa T J Pediatr Gastroenterol Nutr; 1987; 6(1):42-5. PubMed ID: 2432210 [TBL] [Abstract][Full Text] [Related]
8. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma]. Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809 [TBL] [Abstract][Full Text] [Related]
9. The effects of vitamin K on the generation of des-gamma-carboxy prothrombin (PIVKA-II) in patients with hepatocellular carcinoma. Sakon M; Monden M; Gotoh M; Kobayashi K; Kanai T; Umeshita K; Endoh W; Mori T Am J Gastroenterol; 1991 Mar; 86(3):339-45. PubMed ID: 1705389 [TBL] [Abstract][Full Text] [Related]
10. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma. Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546 [TBL] [Abstract][Full Text] [Related]
11. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Yoon YJ; Han KH; Kim DY Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065 [TBL] [Abstract][Full Text] [Related]
12. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708 [TBL] [Abstract][Full Text] [Related]
13. [Serum vitamin K content in patients with hepatocellular carcinoma with special reference to plasma PIVKA-II levels]. Fujiyama S; Morishita A; Iida S; Sagara K; Sato T; Motohara K; Matsuda I; Shirahata S Nihon Shokakibyo Gakkai Zasshi; 1986 Jun; 83(6):1229. PubMed ID: 3020286 [No Abstract] [Full Text] [Related]
14. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA. Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance. Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727 [TBL] [Abstract][Full Text] [Related]
16. Vitamin K contents in liver tissue of hepatocellular carcinoma patients. Miyakawa T; Kajiwara Y; Shirahata A; Okamoto K; Itoh H; Ohsato K Jpn J Cancer Res; 2000 Jan; 91(1):68-74. PubMed ID: 10744046 [TBL] [Abstract][Full Text] [Related]
17. Serum tests for diagnosis and follow-up of hepatocellular carcinoma after treatment. Trojan J; Raedle J; Zeuzem S Digestion; 1998 Jul; 59 Suppl 2():72-4. PubMed ID: 9718428 [No Abstract] [Full Text] [Related]
18. [The clinical significance of PIVKA-II determination in patients with hepatocellular carcinoma: a comparative study with alpha-fetoprotein]. Sakon M; Monden M; Goto M; Kanai T; Umeshita K; Endo W; Mori T Nihon Geka Gakkai Zasshi; 1990 May; 91(5):588-93. PubMed ID: 1696680 [TBL] [Abstract][Full Text] [Related]
19. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases. Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046 [TBL] [Abstract][Full Text] [Related]
20. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients. Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]